Digitally mining tumors for therapy response markers
Nature Medicine
June 11, 2012
Lower amounts of an enzyme called DUSP4 are associated with resistance to neadjuvant chemotherapy-which is given before surgical tumor removal-and aggressive breast cancers, reports a paper published online this week in Nature Medicine. Further validation in clinical trials will confirm whether DUSP4 could be a potential marker of therapy outcome.
Neadjuvant chemotherapy, which is given before surgical tumor removal, can reduce the size of the tumor. But many patients do not have a complete response and show residual cancer after this treatment and an increased risk for metastatic disease.
Using digital DNA quantification in surgically-resected tumors after neo-adjuvant chemotherapy, Carlos Arteaga and colleagues show that the levels of DUSP4, a negative regulator of oncogenic signaling, are decreased in breast cancer patients with poor outcome and short survival. Activation of the oncogenic Ras-ERK pathway seems to be the result of decreased DUSP4, causing impaired cancer cell apoptosis.
The findings suggest that this signaling pathway may be targeted to improve the response to chemotherapy.
doi: 10.1038/nm.2795
Research highlights
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
Jun 23
Scientific community: Women credited less than men in scientific paper authorshipNature
-
Jun 17
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
Jun 17
Conservation: Feral cats pushing critically endangered marsupial further towards extinctionScientific Reports
-
Jun 16
Microbiology: DNA analysis indicates origins of the Black DeathNature